Skip to main content
FDA Shortage Check

Is Ultiva (Remifentanil Hydrochloride Injection) in shortage?

Label: plusbeauxjours · shortage label · not a prescription, not a pharmacy, not FDA

IN SHORTAGE

Ultiva: in shortage (FDA, Oct 24)

Injections (vials)
A generic injection, not your medicine. We draw dosage forms, not products, and never pills you could match to yours.
  • Reason: “Delay in shipping of the drug”. FDA shortage reason (FDASIA), reported by the manufacturer
  • Reason: “Demand increase for the drug”. FDA shortage reason (FDASIA), reported by the manufacturer
  • Estimate: “Estimated recovery: TBD”. Manufacturer’s estimate, Hikma Pharmaceuticals USA, Inc., Oct 14, 2026
DRUG
Ultiva
FDA LISTING
FORM
injection
STATUS
Currently in Shortage
FIRST POSTED
Jun 28, 2022
LAST FDA UPDATE
Oct 19, 2026
AS OF
Oct 24, 2026
SOURCE

FDA lists 9 presentations: 4 unavailable · 0 limited · 5 available.

FDA Drug Shortages checked Oct 24, 2026, 21:05 ET · FDA updates daily · manufacturer-reported

Information from FDA’s drug shortage list, reported by manufacturers. Not medical advice. Don’t stop, change or ration a medicine without talking to your prescriber or pharmacist.

FDA's listing, word for word: Remifentanil Hydrochloride Injection. 9 presentations from 3 makers.

Check your own medication, form and strength

What to ask at the counter

  1. Is this a supply problem at this pharmacy, or everywhere? Could another pharmacy have it? FDA consumer FAQ (opens in a new tab)
  2. Is my strength or the maker you stock affected? FDA list, by presentation
  3. Is there an alternative to this medicine I should ask my prescriber about? FDA consumer FAQ (opens in a new tab)
  4. When should I check back, or can you order it?

FDA: “talk with your health care provider or pharmacist for other treatment options during the shortage.” FDA Drug Shortages page (opens in a new tab)

This listing on FDA ↗ (opens in a new tab)Report a shortage to FDA: drugshortages@fda.hhs.gov

Every presentation FDA lists, by maker

Availability is FDA's text for each package, as the manufacturer reported it. Makers with unavailable or limited packages come first.

Fresenius Kabi USA, LLC3 presentations · 1 unavailable · 2 available or not stated

Contact (FDA's listing): 888-386-1300

  • 1 mg/1 mL

    Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)

    Next release November 2026. Check wholesalers for inventory.

    NDC 63323-723-03Revised

    Unavailable

  • 1 mg/1 mL

    Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)

    Check wholesalers for inventory

    NDC 63323-724-05Reverified

    Available

  • 1 mg/1 mL

    Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)

    Check wholesalers for inventory

    NDC 63323-725-10Reverified

    Available

Hikma Pharmaceuticals USA, Inc.3 presentations · 3 unavailable

Contact (FDA's listing): 800-631-2174

  • 1 mg per vial

    Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)

    Estimated recovery: TBD

    NDC 0143-9391-10Reverified

    Unavailable

  • 2 mg per vial

    Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)

    Estimated recovery: TBD

    NDC 0143-9392-10Reverified

    Unavailable

  • 5 mg per vial

    Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)

    Estimated recovery: TBD

    NDC 0143-9393-10Revised

    Unavailable

Mylan Institutional, a Viatris Company3 presentations · 3 available or not stated

Contact (FDA's listing): 800-796-9526

  • 1 mg/1 mL

    Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)

    NDC 72078-034-01Reverified

    Available

  • 2 mg

    Ultiva, Injection, 2 mg (NDC 72078-035-02)

    NDC 72078-035-02Reverified

    Available

  • 5 mg

    Ultiva, Injection, 5 mg (NDC 72078-036-05)

    NDC 72078-036-05Reverified

    Available

What the manufacturers told FDA

  • Fresenius Kabi USA, LLC · ‘Next release November 2026. Check wholesalers for inventory.’ · updated Oct 2026
  • Hikma Pharmaceuticals USA, Inc. · ‘Estimated recovery: TBD’ · updated Oct 2026

More on FDA ↗ (opens in a new tab)

Reason for the shortage (FDASIA)

  • Delay in shipping of the drug
  • Demand increase for the drug

As reported by the manufacturer under the Food and Drug Administration Safety and Innovation Act.

Alternatives

FDA lists none: “Providing a list of alternative drug products for a drug in shortage is part of the ‘practice of medicine.’ FDA does not regulate the practice of medicine.” Your prescriber or pharmacist can talk through options with you. ASHP also tracks shortages and suggested alternatives (different criteria) ↗ (opens in a new tab)

Questions

Is Ultiva in shortage?
Yes. As of Oct 24, 2026, FDA lists Remifentanil Hydrochloride Injection as currently in shortage: 9 presentations, 4 unavailable and 0 limited.
When will the Ultiva shortage end?
FDA gives no end date. 3 presentations carry a manufacturer’s own estimate, quoted on this page with its date.
Does FDA list alternatives to Ultiva?
No. FDA calls a list of alternatives part of the ‘practice of medicine’. Ask your pharmacist or prescriber.